MedTrace Logo

Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT03321890 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2017-10-26

No results posted yet for this study

Summary

To observe the efficacy and safety of Chidamide combined with prednisone, cyclophosphamide, etoposide and methotrexate in relapsed or refractory PTCL.

Conditions

  • Peripheral T-cell Lymphoma

Interventions

DRUG

Chidamide

Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast

DRUG

prednisone

oral, 20mg / day,after breakfast

DRUG

Cyclophosphamide

oral, 50mg / day,after lunch

DRUG

etoposide

oral, 50mg / day,after dinner

DRUG

Methotrexate

oral, 10mg / times, once a week,after breakfast

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Wenqi Jiang, MD · Department of Medical Oncology,Sun Yat-Sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-07
Primary Completion
2020-12-01
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03321890 on ClinicalTrials.gov